Ubix Therapeutics’ Post

Streamline Preclinical Drug Discovery: PBMC-Humanised Mouse Models Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In this bispecific case study, learn how the platform: - Captured donor-specific responses and their impact on efficacy and safety profiles - Identified potential toxicity risks  - Correlated cytokine release and tumour growth inhibition in the context of bispecifics - Seize this opportunity to gain valuable insights into the future of efficient preclinical drug discovery and development. Download Case Study https://lnkd.in/eQqpE6v8 Brought to you by The Jackson Laboratory #DrugDiscovery #DrugDevelopment #TCells Jackson Laboratories

🚨 Capricor Therapeutics to File BLA for Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Treatment 🚨 Capricor Therapeutics, a leader in innovative cell and exosome-based therapies, announced plans to file a Biologics License Application (BLA) for *deramiocel* following discussions with the FDA. The filing will focus on treating DMD cardiomyopathy using existing cardiac data. Key updates: 📅 BLA Filing Timeline: Filing begins October 2024, with full submission anticipated by year-end. 📊 Data Sources:  Application will leverage Phase 2 HOPE-2 and HOPE-2 OLE trial data, alongside natural history data from Vanderbilt University and Cincinnati Children’s Hospital. 🔬 Next Steps for Skeletal Muscle Myopathy Treatment: Capricor plans to combine cohorts from the Phase 3 HOPE-3 trial for post-approval study, deferring the unblinding of Cohort A. A major milestone in the fight against DMD – stay tuned for more updates! #biotech #FDA #capricor #duchennemusculardystrophy #healthcareinnovation Karan Chechi | Alwin Samuel | Shaurya Singh | TechSci Research

Dianthus Therapeutics presented promising preclinical data for its autoimmune drug candidate, DNTH103, in models of myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. The drug showed significant reductions in fatigue index for myasthenia gravis patients and restored neuronal conduction velocity in CIDP patients. DNTH103 targets the complement pathway with a selective mechanism of action to potentially lower the risk of infections compared to current treatment options. Dianthus is actively progressing with clinical trials for DNTH103, with Phase 2 trials underway and FDA clearance obtained for further studies in related conditions. #autoimmune #preclinicaldata #DNTH103 #neurologicaldisorders #clinicaltrials Read more here: https://lnkd.in/ehrVMURB BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

InMed's INM-901 is a small molecule drug candidate demonstrating multiple pharmacological effects in the potential treatment of #Alzheimer's disease. Watch this video presentation by InMed’s CEO, Eric A. Adams, as he shares the preclinical data on INM-901: https://ow.ly/Vlls50T2ygH $INM #AlzheimersDisease

Are you attending? Please look for our poster: "Critical Path Institute Expands Data Analytics to Mitochondrial and Inherited Metabolic Diseases" Wellcome Connecting Science Learning and Training Amanda Klein mitoworld.org Critical Path Institute (C-Path) #leighsyndrome #mitochondrialdisease

✨ Only 2 days until we arrive in Basel! ✨ Join us to meet our Co-founders: Chris Steffi, Barna Gal, MD, and Robert Baumann. 📊 Don’t miss our poster presentation on Bon3OID™-OC, our 3D organotypic model 🧬 that replicates bone remodeling—an advanced tool for testing compounds in preclinical drug development for bone-related disorders. 👋 See you in Basel! #Innovation #Partnering #3R #BoneHealth #OrganotypicBoneModels #InVitroBoneModels #RheumatoidArthritis #BoneOncology #BoneMetastases #RareBoneDiseases #BoneBiology #Osteoporosis

#OneTechnologyAMonth series March 2024 - Differential Scanning Calorimetry There is power in numbers: using DSC as one of the orthogonal techniques for assessment of LNP-RNA therapeutics https://lnkd.in/e5YDkQYm

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

🔬 We will be attending the 6th Macrophage-Directed Therapies Summit 2024 in Boston, MA from October 1-3, 2024! 👉 https://lnkd.in/ejDm6xDJ On Thursday, October 3, 2024 at 9:30 a.m. EDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "How to enhance translatability of myeloid-targeted therapies in preclinical models" The presentation will focus on: ▶ #BRGSF-HIS mouse: the only CD34+-reconstituted model with functional human lymphoid and myeloid compartments without side effects ▶ Myeloid cells functionality and assessment of immune modulation induced by biologics in the model ▶ Safety studies in the BRGSF-HIS model to investigate immune-related adverse effects Read more on the BRGSF-HIS model here 👉 https://lnkd.in/eUav-Ra5 #macrophagedirectedtherapiessummit #preclinicalmodels #cancerresearch 

This podcast recording from the 2023 PODD: Partnership Opportunities in Drug Delivery Conference focuses on transnasal delivery of therapeutics to the brain and features representatives from Harvard Medical School, Eli Lilly and Company, and Seelos Therapeutics, Inc. Listen to the podcast here: https://lnkd.in/e9vBXqC6 #PODD2023 #PODD2024 #DrugDelivery #Formulations #Transnasal #therapeutics #DrugDevelopment